CY1121692T1 - Παραγωγα 5-[(πιπεραζιν-1-υλ)-3-οξο-προπυλ]-ιμιδαζολιδινο-2,4-διονης ως αναστολεις adamts για τη θεραπεια οστεοαρθριτιδας - Google Patents

Παραγωγα 5-[(πιπεραζιν-1-υλ)-3-οξο-προπυλ]-ιμιδαζολιδινο-2,4-διονης ως αναστολεις adamts για τη θεραπεια οστεοαρθριτιδας

Info

Publication number
CY1121692T1
CY1121692T1 CY20191100464T CY191100464T CY1121692T1 CY 1121692 T1 CY1121692 T1 CY 1121692T1 CY 20191100464 T CY20191100464 T CY 20191100464T CY 191100464 T CY191100464 T CY 191100464T CY 1121692 T1 CY1121692 T1 CY 1121692T1
Authority
CY
Cyprus
Prior art keywords
treatment
imidazolidino
piperazin
osteoarthritis
oxo
Prior art date
Application number
CY20191100464T
Other languages
English (en)
Inventor
Franck Laurent BREBION
Luke Jonathan ALVEY
David Amantini
Pierre Marc Marie Joseph DEPREZ
Romain Luc Marie Gosmini
Helène Marie JARY
Christophe Peixoto
Marie Laurence Claire VARIN
Frédéric André DE CEUNINCK
Iuliana Ecaterina POP-BOTEZ
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of CY1121692T1 publication Critical patent/CY1121692T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αποκαλύπτει ενώσεις σύμφωνα προς τον Τύπο (I), όπου R, R2, R3a, R3b και Cy είναι όπως ορίζονται στο παρόν. Η παρούσα εφεύρεση αποκαλύπτει ενώσεις που αναστέλλουν ADAMTS, μεθόδους για την παραγωγή αυτών, φαρμακευτικές συνθέσεις που περιλαμβάνουν τις ίδιες και μεθόδους για την προφύλαξη ή/και θεραπεία φλεγμονωδών καταστάσεων ή/και ασθενειών που ενέχουν αποικοδόμηση του χόνδρου ή/και διαταραχή της ομοιόστασης χόνδρου.
CY20191100464T 2014-12-22 2019-05-02 Παραγωγα 5-[(πιπεραζιν-1-υλ)-3-οξο-προπυλ]-ιμιδαζολιδινο-2,4-διονης ως αναστολεις adamts για τη θεραπεια οστεοαρθριτιδας CY1121692T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14307129 2014-12-22
PCT/EP2015/080430 WO2016102347A1 (en) 2014-12-22 2015-12-18 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
CY1121692T1 true CY1121692T1 (el) 2020-07-31

Family

ID=52345014

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100464T CY1121692T1 (el) 2014-12-22 2019-05-02 Παραγωγα 5-[(πιπεραζιν-1-υλ)-3-οξο-προπυλ]-ιμιδαζολιδινο-2,4-διονης ως αναστολεις adamts για τη θεραπεια οστεοαρθριτιδας

Country Status (49)

Country Link
US (4) US9926281B2 (el)
EP (2) EP3237406B1 (el)
JP (2) JP6636539B2 (el)
CN (1) CN107108579B (el)
AR (1) AR103170A1 (el)
AU (1) AU2015371400B2 (el)
BR (1) BR112017013258B1 (el)
CA (1) CA2971110C (el)
CL (1) CL2017001650A1 (el)
CO (1) CO2017006174A2 (el)
CR (1) CR20170248A (el)
CU (1) CU20170085A7 (el)
CY (1) CY1121692T1 (el)
DK (1) DK3237406T3 (el)
DO (1) DOP2017000139A (el)
EA (1) EA030637B1 (el)
EC (1) ECSP17046848A (el)
ES (1) ES2724989T3 (el)
GE (1) GEP20197043B (el)
GT (1) GT201700107A (el)
HK (1) HK1245793B (el)
HR (1) HRP20190514T1 (el)
HU (1) HUE042840T2 (el)
IL (1) IL252981B (el)
JO (1) JO3501B1 (el)
LT (1) LT3237406T (el)
MA (1) MA41238B1 (el)
MD (1) MD3237406T2 (el)
ME (1) ME03374B (el)
MX (1) MX2017008048A (el)
MY (1) MY189764A (el)
NI (1) NI201700081A (el)
NZ (1) NZ732909A (el)
PE (1) PE20171099A1 (el)
PH (1) PH12017501160A1 (el)
PL (1) PL3237406T3 (el)
PT (1) PT3237406T (el)
RS (1) RS58617B1 (el)
RU (1) RU2693459C2 (el)
SA (1) SA517381743B1 (el)
SG (1) SG11201705030SA (el)
SI (1) SI3237406T1 (el)
TN (1) TN2017000213A1 (el)
TR (1) TR201904158T4 (el)
TW (1) TWI687414B (el)
UA (1) UA122065C2 (el)
UY (1) UY36470A (el)
WO (1) WO2016102347A1 (el)
ZA (1) ZA201703905B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3501B1 (ar) 2014-12-22 2020-07-05 Servier Lab مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام)
GB201610055D0 (en) * 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
GB201610056D0 (en) * 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
CN107652277A (zh) * 2017-08-09 2018-02-02 江苏工程职业技术学院 一种依帕列净的制备方法
CN107540648A (zh) * 2017-08-09 2018-01-05 江苏工程职业技术学院 一种达格列净的制备方法
WO2021011720A2 (en) * 2019-07-18 2021-01-21 Avidence Therapeutics, Inc. Anti-osteoarthritis compounds and related compositions and methods
JP2023513121A (ja) * 2020-02-04 2023-03-30 江蘇恒瑞医薬股▲ふん▼有限公司 Ａｄａｍｔｓ阻害剤、その製造および医薬用途
WO2021204185A1 (zh) * 2020-04-10 2021-10-14 深圳信立泰药业股份有限公司 一种苯并[d]氮杂卓类衍生物蛋白聚糖酶2抑制剂及其制备方法和医药用途
CN113735825B (zh) * 2020-05-27 2024-08-27 成都康弘药业集团股份有限公司 1,2,3,6-四氢吡啶类化合物及其制备方法和用途
CN113754635B (zh) * 2020-06-02 2024-06-21 成都康弘药业集团股份有限公司 稠环类化合物及其制备方法和用途
CN115720578A (zh) * 2020-07-09 2023-02-28 深圳信立泰药业股份有限公司 并三环类衍生物、其制备方法及其在医药上的应用
CN113943255B (zh) * 2020-07-17 2024-08-06 深圳信立泰药业股份有限公司 一种手性3-(4-环丙基-2,5-二氧杂咪唑啉-4-基)丙酸的制备方法
AU2021399788A1 (en) 2020-12-15 2023-08-03 Galapagos Nv Solid forms of (5s)-cyclopropyl-5-[3-[(3s)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione
WO2022212638A1 (en) * 2021-04-02 2022-10-06 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Prodrugs of adamts inhibitors, preparation methods and medicinal uses thereof
TW202321221A (zh) * 2021-08-03 2023-06-01 大陸商江蘇恒瑞醫藥股份有限公司 抑制adamts-5和/或adamts-4功能的化合物的晶型及其製備方法和應用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556670A (en) * 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications
US4680306A (en) * 1984-07-20 1987-07-14 Pfizer Inc. Sprio-imidazolones for treatment of diabetes complications
US5043447A (en) * 1987-04-24 1991-08-27 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
DE60234028D1 (de) 2001-05-25 2009-11-26 Bristol Myers Squibb Co Hydantion-derivate als hemmer von matrix-metalloproteinasen
GB0405101D0 (en) 2004-03-06 2004-04-07 Astrazeneca Ab Compounds
US7504424B2 (en) * 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
EP2650310B1 (en) 2012-04-13 2016-06-08 Rottapharm Biotech S.r.l. Anti-ADAMTS-5 antibody, derivatives and uses thereof
AR092971A1 (es) * 2012-10-26 2015-05-06 Lilly Co Eli Inhibidores de agrecanasa
WO2014121884A1 (en) 2013-02-06 2014-08-14 Merck Patent Gmbh Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis
JO3501B1 (ar) * 2014-12-22 2020-07-05 Servier Lab مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام)

Also Published As

Publication number Publication date
SG11201705030SA (en) 2017-07-28
CL2017001650A1 (es) 2018-01-26
ME03374B (me) 2020-01-20
BR112017013258B1 (pt) 2023-02-07
IL252981A0 (en) 2017-08-31
HK1245793B (zh) 2020-01-03
ES2724989T3 (es) 2019-09-18
PT3237406T (pt) 2019-03-19
CA2971110A1 (en) 2016-06-30
BR112017013258A8 (pt) 2022-08-16
DOP2017000139A (es) 2017-10-31
PH12017501160A1 (en) 2017-12-11
RS58617B1 (sr) 2019-05-31
WO2016102347A1 (en) 2016-06-30
EA201791451A1 (ru) 2017-11-30
KR20170122720A (ko) 2017-11-06
CN107108579B (zh) 2019-12-17
US10487060B2 (en) 2019-11-26
MY189764A (en) 2022-03-03
US20180002293A1 (en) 2018-01-04
DK3237406T3 (da) 2019-05-06
TR201904158T4 (tr) 2019-05-21
JP2020063278A (ja) 2020-04-23
JP2018502906A (ja) 2018-02-01
MA41238A (fr) 2017-11-01
RU2017126187A3 (el) 2019-01-24
US11718588B2 (en) 2023-08-08
BR112017013258A2 (pt) 2018-02-06
EA030637B1 (ru) 2018-09-28
EP3237406A1 (en) 2017-11-01
TWI687414B (zh) 2020-03-11
ECSP17046848A (es) 2017-10-31
US10941117B2 (en) 2021-03-09
AU2015371400A1 (en) 2017-07-06
GT201700107A (es) 2019-08-07
GEP20197043B (en) 2019-11-25
UY36470A (es) 2016-07-29
SI3237406T1 (sl) 2019-04-30
CN107108579A (zh) 2017-08-29
AU2015371400B2 (en) 2019-07-25
PE20171099A1 (es) 2017-08-07
CA2971110C (en) 2023-05-16
TW201629041A (zh) 2016-08-16
MA41238B1 (fr) 2019-04-30
CU20170085A7 (es) 2017-10-05
JP6636539B2 (ja) 2020-01-29
JO3501B1 (ar) 2020-07-05
CO2017006174A2 (es) 2017-09-11
RU2017126187A (ru) 2019-01-24
MX2017008048A (es) 2017-10-19
NZ732909A (en) 2020-08-28
US20210309614A1 (en) 2021-10-07
IL252981B (en) 2019-07-31
US20180258052A1 (en) 2018-09-13
US9926281B2 (en) 2018-03-27
US20200216397A1 (en) 2020-07-09
AR103170A1 (es) 2017-04-19
NI201700081A (es) 2017-09-08
UA122065C2 (uk) 2020-09-10
EP3237406B1 (en) 2019-02-06
HRP20190514T1 (hr) 2019-05-03
HUE042840T2 (hu) 2019-07-29
TN2017000213A1 (en) 2018-10-19
ZA201703905B (en) 2022-03-30
RU2693459C2 (ru) 2019-07-03
PL3237406T3 (pl) 2019-07-31
MD3237406T2 (ro) 2019-05-31
EP3575294A1 (en) 2019-12-04
SA517381743B1 (ar) 2021-01-28
LT3237406T (lt) 2019-03-25
CR20170248A (es) 2017-07-19

Similar Documents

Publication Publication Date Title
CY1121692T1 (el) Παραγωγα 5-[(πιπεραζιν-1-υλ)-3-οξο-προπυλ]-ιμιδαζολιδινο-2,4-διονης ως αναστολεις adamts για τη θεραπεια οστεοαρθριτιδας
CY1120969T1 (el) Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1122918T1 (el) Προφαρμακα ενωσης αναστολεα jak για την θεραπεια μιας γαστρεντερικης φλεγμονωδους νοσου
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CY1120029T1 (el) Παραγωγα 6-(5-υδροξυ-1η-πυραζολ-1-υλ) νικοτιναμιδιου και χρηση τους ως αναστολεις phd
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CY1121444T1 (el) Παραγωγα κιnoλonης ως αναστoλεις υποδοχεα αυξητικου παραγοντα ινοβλαστων
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
BR112015030203A2 (pt) moléculas pequenas inibidores da fibrose
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
CY1123349T1 (el) Ενωσεις 6-ετεροκυκλυλ-4-μορφολιν-4-υλπυρiδιν-2-οnhς χρησιμες για τη θεραπεια καρκινου και διαβητη
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
CY1121746T1 (el) Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης
CY1121554T1 (el) Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
CY1124838T1 (el) Αλας παραγωγου κεφαλοσπορινης, κρυσταλλικη, στερεη μορφη αυτου και μεθοδος παραγωγης αυτου
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam
PL408052A1 (pl) Nowa pochodna kwasu 5-amino-3-metylo-4-izoksazolokarboksylowego, sposób jej wytwarzania i zastosowanie